secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-169077
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve Eliem-Tenet merger; closing expected June 27, 2024
-----------------------------------------------------------------------

- Share Issuance Proposal passed: 26,311,239 for, 3,253 against; disinterested approval 12,655,083 for.
- Directors Andrew Levin and Liam Ratcliffe elected to board until 2027.
- PricewaterhouseCoopers ratified as independent auditor for FY2024.
- Acquisition of Tenet Medicines and concurrent PIPE expected to close on or about June 27, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524169077/0001193125-24-169077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524169077/d788381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-169077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer